CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
Kisspeptin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04958109
NCT04958109Phase 1Completed
CompareCT.gov

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

Massachusetts General Hospital·interventional·Posted Jul 12, 2021·Updated Mar 6, 2026

In Brief

A Phase 1 clinical trial evaluating Oral Glucose Tolerance Test, Kisspeptin, and 1 other intervention for Metabolic Diseases. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Diseases
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedJul 12, 2021
Enrollment StartOct 28, 2021
Primary CompletionOct 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.0 years ago

Interventions

Oral Glucose Tolerance Testother

Administration of a 75 gm oral glucose tolerance test

Kisspeptindrug

Intravenous administration of kisspeptin 112-121 x 16 hours

Placebodrug

Intravenous administration of Placebo 16 hours